Clinical and Translational Radiation Oncology (Sep 2020)
MRI detected extaprostatic extension (EPE) in prostate cancer: Do all T3a patients have the same outcomes?
- A. Gomez-Iturriaga,
- D. Büchser,
- I. San Miguel,
- M. Marban,
- A. Urresola,
- A. Ezquerro,
- A. Gil,
- F. Suarez,
- A. Gonzalez,
- E. Mairata,
- L. Martinez-Indart,
- J. Cacicedo,
- F. Couñago,
- P. Mínguez,
- F. Casquero
Affiliations
- A. Gomez-Iturriaga
- Hospital Universitario Cruces/Biocruces Bizkaia Health Research Institute, Radiation Oncology, Barakaldo, Spain; Corresponding author at: Department of Radiation Oncology, Hospital Universitario Cruces, Plaza Cruces Gurutzeta 12, 48903 Barakaldo, Spain.
- D. Büchser
- Hospital Universitario Cruces/Biocruces Bizkaia Health Research Institute, Radiation Oncology, Barakaldo, Spain
- I. San Miguel
- Hospital Universitario Cruces/Biocruces Bizkaia Health Research Institute, Radiation Oncology, Barakaldo, Spain
- M. Marban
- Hospital Universitario Cruces/Biocruces Bizkaia Health Research Institute, Radiation Oncology, Barakaldo, Spain; Hospital Universitario Cruces/Biocruces Bizkaia Health Research Institute, Radiation Oncology, Barakaldo, Spain
- A. Urresola
- Hospital Universitario Cruces/Biocruces Bizkaia Health Research Institute, Radiation Oncology, Barakaldo, Spain
- A. Ezquerro
- Hospital Universitario Cruces/Biocruces Bizkaia Health Research Institute, Radiation Oncology, Barakaldo, Spain
- A. Gil
- Hospital Universitario Cruces/Biocruces Bizkaia Health Research Institute, Radiation Oncology, Barakaldo, Spain
- F. Suarez
- Hospital Universitario Cruces/Biocruces Bizkaia Health Research Institute, Radiation Oncology, Barakaldo, Spain
- A. Gonzalez
- Hospital Universitario Cruces/Biocruces Bizkaia Health Research Institute, Radiation Oncology, Barakaldo, Spain
- E. Mairata
- Hospital Universitario Cruces/Biocruces Bizkaia Health Research Institute, Radiation Oncology, Barakaldo, Spain
- L. Martinez-Indart
- Hospital Universitario Cruces/Biocruces Health Research Institute, Clinical Epidemiology Unit, Barakaldo, Spain
- J. Cacicedo
- Hospital Universitario Cruces/Biocruces Bizkaia Health Research Institute, Radiation Oncology, Barakaldo, Spain
- F. Couñago
- Department of Radiation Oncology, Hospital Universitario Quirón salud Madrid, 28223 Pozuelo de Alarcón, Madrid, Spain
- P. Mínguez
- Hospital Universitario Cruces/Biocruces Bizkaia Health Research Institute, Radiation Oncology, Barakaldo, Spain
- F. Casquero
- Hospital Universitario Cruces/Biocruces Bizkaia Health Research Institute, Radiation Oncology, Barakaldo, Spain
- Journal volume & issue
-
Vol. 24
pp. 135 – 139
Abstract
MRI-detected T3a prostate cancer is a heterogeneous disease. This post-hoc analysis of a prospective trial found that patients with T3a disease presenting obliteration of the recto-prostatic angle, contact-asymmetry of neuro-vascular bundle and periprostatic fat invasion, may be at higher risk of biochemical failure and metastases.
